Immunic, Inc. insider trading

Every open-market purchase and sale by Immunic, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Immunic, Inc.’s insiders pay?

From June 4, 2014 to June 16, 2025, 15 insiders reported 45 open-market purchases and 4 sales not made under a pre-set plan in Immunic, Inc. Twelve months after each purchase was reported, the shares were −62.0% against the S&P 500 on average (median −74.1%), over 21 purchases with a full year of prices; 5% beat the index. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on June 5, 2014 into $10 by November 2, 2026, −42.9% a year. It held shares 54% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $22,924 (+6.9% a year), and held throughout $47,926 (+13.5%).

Copying Immunic, Inc.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Immunic, Inc.'s insiders from June 5, 2014, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 54% of the time.

Immunic, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Satter Muneer A	Director	11	−56.2% (5)	20%	1	—	September 17, 2018
Whaley Glenn	Chief Financial Officer	6	−61.7% (4)	0%	0	—	June 4, 2025
Bienaime Jean Jacques	Director	4	−74.1% (1)	0%	0	—	September 14, 2017
Nash Duane	Executive Chairman	4	−66.6% (2)	0%	0	—	June 16, 2025
Vitt Daniel	CEO and Director	4	—	—	0	—	June 6, 2025
Hasnain Faheem	Director	2	−70.8% (1)	0%	1	—	September 17, 2018
Neermann Joerg	Director	3	—	—	0	—	June 5, 2025
Godshall Douglas Evan	Director	1	−74.1% (1)	0%	1	—	September 21, 2018
Halperin Errol R.	Director	1	−74.1% (1)	0%	1	—	September 25, 2018
Muehler Andreas	Chief Medical Officer	2	−61.1% (2)	0%	0	—	May 16, 2022
Rudick Richard Alan	Director	2	—	—	0	—	June 4, 2025
Winters Terence E.	Co-Chairman and CEO	2	−67.4% (1)	0%	0	—	June 15, 2017
Cohen Cheryl	Director	1	−41.9% (1)	0%	0	—	October 27, 2015
Dunn John Michael	General Counsel and Secretary	1	−41.9% (1)	0%	0	—	October 27, 2015
Sears Lowell	Director	1	−74.1% (1)	0%	0	—	October 9, 2014

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Immunic, Inc.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Immunic, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 4 buying crowds with six months of prices, it averaged −21.5% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
May 31, 2022	3 buying	−22.7%	−75.1%	−77.8%
March 31, 2021	2 buying	−31.4%	−53.3%	−44.8%
October 30, 2015	4 buying	+22.2%	+6.1%	−35.6%
October 31, 2014	6 buying	+16.2%	+36.2%	−57.0%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Immunic, Inc. · Funds · Politicians